Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30165233 | 0.82 | KMT2A (0.46) | RAB9APOLBALDH1A1KMT2ATSHR | |
| SCHEMBL23884267 | 0.82 | KMT2A (0.46) | RAB9APOLBALDH1A1KMT2ATSHR | |
| SCHEMBL23917150 | 0.81 | RAB9A (0.44) | RAB9APOLBALDH1A1KMT2ATSHR | |
| SCHEMBL23907990 | 0.80 | ALDH1A1 (0.47) | POLBALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL23884376 | 0.74 | ALDH1A1 (0.46) | RAB9APOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL23907985 | 0.71 | ALDH1A1 (0.47) | POLBALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL23907980 | 0.70 | ALDH1A1 (0.51) | ALDH1A1KMT2ATSHRMEN1GAA | |
| SCHEMBL23907995 | 0.69 | ALDH1A1 (0.47) | ALDH1A1KMT2ATSHRMEN1L3MBTL1 | |
| SCHEMBL1623258 | 0.68 | EPHX2 (0.61) | RAB9APOLBALDH1A1KMT2AMEN1 | |
| SCHEMBL23884283 | 0.67 | ALDH1A1 (0.46) | POLBALDH1A1KMT2ATSHRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-06-09 | — | — | US | disclosed |
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | SOUTHERN RES INST (US) | 2021-10-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210317106-A1 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | RAB9A 1756/4885POLB 2683/4885ALDH1A1 492/4885 |
| US-20220177452-A9 | 2-Pyrimidone Analogs as Potent Antiviral Agents Against Alphaviruses | EIF2AK2, ZC3HAV1, MAVS | RAB9A 1756/4885POLB 2683/4885ALDH1A1 492/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.